Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

MERCK AND COMPANY

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

AstraZeneca, Merck Get FDA Priority Review for Lynparza in Form of Prostate Cancer

share with twitter share with LinkedIn share with facebook
share via e-mail
01/21/2020 | 07:29am EST

By Colin Kellaher

AstraZeneca PLC (AZN, AZN.LN) and Merck & Co. (MRK) on Tuesday said the U.S. Food and Drug Administration accepted and granted priority review to a supplemental new-drug application for Lynparza in a form of prostate cancer.

The drugmakers said the filing covers the treatment of patients with metastatic castration-resistant prostate cancer and deleterious or suspected deleterious germline or somatic homologous recombination repair gene mutations, who have progressed following prior treatment with a new hormonal agent.

The FDA grants priority review to medicines that have the potential to provide significant improvements in the treatment of a serious disease, and the designation shortens the review period.

AstraZeneca and Merck, which in 2017 formed a collaboration to co-develop and co-commercialize AstraZeneca's Lynparza for multiple cancer types, said the agency has set a target action date for the second quarter.

Write to Colin Kellaher at colin.kellaher@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 1.39% 7677 Delayed Quote.-0.43%
MERCK AND COMPANY 0.60% 82.49 Delayed Quote.-9.30%
MERCK KGAA 0.53% 123.4 Delayed Quote.16.52%
MRK HOLDINGS INC. 0.00% 212 End-of-day quote.-1.40%
PROCTER & GAMBLE COMPANY 0.91% 126.58 Delayed Quote.1.35%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on MERCK AND COMPANY
02/20EXCLUSIVE : Canadian regulator considers changes to new drug pricing plan
RE
02/20Seattle Genetics and Astellas Receive FDA Breakthrough Therapy Designation fo..
AQ
02/19Merck KGaA sells allergy unit to Dermapharm, keeps autoinjector project
RE
02/19Merck KGaA Sells Allergy Business to Dermapharm
DJ
02/19MERCK AND : Receives Complete Response Letter from the US FDA for Supplemental B..
AQ
02/19Immutep Says Interim Phase II TACTI-002 Data Positive
DJ
02/18MERCK : Receives Complete Response Letter from the US FDA for Supplemental Biolo..
BU
02/18Marriott Names Jim Scholefield Chief Information, Digital Officer
DJ
02/18Merck KGaA Chosen to Produce Liquid Biopsy Kits
DJ
02/17MERCK AND : - ERVEBO Now Registered in Four African Countries Within 90 Days of ..
AQ
More news
Financials (USD)
Sales 2020 49 660 M
EBIT 2020 17 752 M
Net income 2020 12 422 M
Debt 2020 17 799 M
Yield 2020 2,93%
P/E ratio 2020 16,9x
P/E ratio 2021 15,7x
EV / Sales2020 4,59x
EV / Sales2021 4,24x
Capitalization 210 B
Chart MERCK AND COMPANY
Duration : Period :
Merck and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 19
Average target price 98,11  $
Last Close Price 82,49  $
Spread / Highest target 29,7%
Spread / Average Target 18,9%
Spread / Lowest Target 9,10%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Sandy Tremps Vice President-R&D IT CIO
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY-9.30%210 018
JOHNSON & JOHNSON2.10%390 914
ROCHE HOLDING AG10.05%298 571
NOVARTIS3.81%217 737
PFIZER-7.53%198 398
NOVO NORDISK AS14.43%150 219